Sort
51,593 grants matching “hepatitis”
Altered Lipid Droplet Trafficking: Role in Alcoholic Fatty Liver Disease
$591,050Carol A Casey · University Of Nebraska Medical Center · R01 · FY2016 · AA
TMEM55B as a molecular determinant of NAFLD
$591,003Marisa Wong Medina · University Of California, San Francisco · R56 · FY2023 · DK
Soft drusen in rhesus macaques as a nonhuman primate model of early age-related macular degeneration
$590,988Glenn Yiu · University Of California At Davis · R01 · FY2021 · EY
Role of IRF3 in Energy and Glucose Homeostasis
$590,987Evan D Rosen · Beth Israel Deaconess Medical Center · R01 · FY2023 · DK
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent
$590,928Radhakrishnan P Iyer · Spring Bank Technologies, Inc. · R01 · FY2012 · AI
Genetic and Metabolic Basis of Familial Lipodystrophies
$590,898Abhimanyu Garg · Ut Southwestern Medical Center · R01 · FY2010 · DK
ANALYSIS OF CHEMICAL STRUCTURES AND THERAPEUTIC ACTIVITY OF AGENTS FOR HIV AND TUBERCULOSIS (CHEMDB)
$590,866Rocco Casagrande · Gryphon Scientific, Llc · N01 · FY2017 · AI
Physiological Ramifications of Chorionic Somatomammotropin Deficiency
$590,866Paul Joseph Rozance · University Of Colorado Denver · R01 · FY2022 · HD
Biomarkers of Alcoholic Hepatitis
$590,790Gavin E Arteel · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · AA
Conceptual and mechanistic insights into the development of diet-induced obesity through disruption of hepatic circadian rhythms by the gut microbiome
$590,778Eugene B Chang · University Of Chicago · R01 · FY2019 · DK
California Emerging Infections Program-ARRA-317
$590,737Arthur L. Reingold · Public Health Foundation Enterprises · U01 · FY2009 · CI
New hepatitis B small molecule inhibitors
$590,721Callisto Pharmaceuticals, Inc. · R41 · FY2002 · AI
Behavioral Aspects of HIV/HCV/HBV risks in New Injectors
$590,687National Development &Res Institutes · R01 · FY2004 · DA
Small GTP Binding Proteins in Gastrointestinal Mucosa
$590,663James R Goldenring · Vanderbilt University Medical Center · R01 · FY2024 · DK
Intestinally restricted LXR agonism in ameliorating liver failure in short gut syndrome
$590,587Gwendalyn J Randolph · Washington University · R01 · FY2025 · DK
Novel HCV vaccine antigens and nanoparticles
$590,566Jiang Zhu · Scripps Research Institute, The · P01 · FY2025 · AI
KINETICS OF HUMAN POSTPRANDIAL LIPOPROTEIN METABOLISM
$590,533Harvard University (Sch Of Public Hlth) · R01 · FY2001 · HL
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
$590,517Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2011 · CA
Atheroregression via Enhanced Reverse Cholesterol Transport
$590,503Henry J. Pownall · Methodist Hospital Research Institute · R01 · FY2012 · HL
Taking aim at HBV eradication using novel NRTIs and Capsid effectors
$590,494Stefan G Sarafianos · Emory University · R01 · FY2018 · AI
A Novel Druggable Epigenetic Vulnerability Pathway in HCC
$590,486Michael R Green · Univ Of Massachusetts Med Sch Worcester · R01 · FY2020 · CA
Molecular Organization of the Organic Cation-Proton Exchanger, MATE1
$590,428Stephen H Wright · University Of Arizona · R01 · FY2010 · DK
CETP and HDL Function in Cardiovascular Diseases
$590,250Yuqing E Chen · University Of Michigan At Ann Arbor · R01 · FY2013 · HL
LIVOPT -- LIVer cirrhosis - Optimizing Prediction of Patient OuTcomes
$590,208Daniela P Ladner · Northwestern University At Chicago · R01 · FY2025 · AG
Advancement of poxvirus inhibitor
$590,147John H Connor · Boston University Medical Campus · R01 · FY2021 · AI